A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor
Abstract Background Although pancreatic neuroendocrine tumors generally have a far better prognosis relative to pancreatic cancer, the varied manifestations lead to treatment-related challenges. Everolimus therapy is generally recommended for patients with advanced pancreatic neuroendocrine tumors;...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Japan Surgical Society
2017-07-01
|
| Series: | Surgical Case Reports |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40792-017-0361-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850045363976667136 |
|---|---|
| author | Asahi Sato Toshihiko Masui Nao Sankoda Kenzo Nakano Yuichiro Uchida Takayuki Anazawa Kyoichi Takaori Yoshiya Kawaguchi Shinji Uemoto |
| author_facet | Asahi Sato Toshihiko Masui Nao Sankoda Kenzo Nakano Yuichiro Uchida Takayuki Anazawa Kyoichi Takaori Yoshiya Kawaguchi Shinji Uemoto |
| author_sort | Asahi Sato |
| collection | DOAJ |
| description | Abstract Background Although pancreatic neuroendocrine tumors generally have a far better prognosis relative to pancreatic cancer, the varied manifestations lead to treatment-related challenges. Everolimus therapy is generally recommended for patients with advanced pancreatic neuroendocrine tumors; however, its efficacy in a neoadjuvant setting remains unclear. Here we present a case of a giant pancreatic neuroendocrine tumor with a portal tumor thrombus that became resectable after everolimus therapy. Case presentation A 62-year-old woman was admitted to our hospital for surgical resection of a giant pancreatic neuroendocrine tumor in the left upper abdomen. Unfortunately, she was ineligible for surgery because the tumor had extended near the hepatic hilus in the portal vein, and she was administered everolimus (10 mg/day). After 2 years of this therapy, the extent of portal vein involvement had decreased, despite the lack of significant changes in the tumor size, and the hepatic hilus became free of disease. She was subsequently referred to us for resection via distal pancreatectomy with portal vein reconstruction because the tumor had begun to grow slowly. Pathological review identified a grade 2 neuroendocrine tumor with no lymph node metastasis. The patient’s postoperative course was uneventful, and she has remained recurrence-free for 27 months, despite a lack of additional treatment. Conclusions Our experience suggests that everolimus could be useful for neoadjuvant therapy in cases of locally advanced pancreatic neuroendocrine tumor. |
| format | Article |
| id | doaj-art-c5f4add6cfad4f55bc23940525dcdb8e |
| institution | DOAJ |
| issn | 2198-7793 |
| language | English |
| publishDate | 2017-07-01 |
| publisher | Japan Surgical Society |
| record_format | Article |
| series | Surgical Case Reports |
| spelling | doaj-art-c5f4add6cfad4f55bc23940525dcdb8e2025-08-20T02:54:42ZengJapan Surgical SocietySurgical Case Reports2198-77932017-07-01311510.1186/s40792-017-0361-8A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumorAsahi Sato0Toshihiko Masui1Nao Sankoda2Kenzo Nakano3Yuichiro Uchida4Takayuki Anazawa5Kyoichi Takaori6Yoshiya Kawaguchi7Shinji Uemoto8Division of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto UniversityDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto UniversityDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto UniversityDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto UniversityDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto UniversityDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto UniversityDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto UniversityDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto UniversityDivision of Hepato-Biliary-Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine, Kyoto UniversityAbstract Background Although pancreatic neuroendocrine tumors generally have a far better prognosis relative to pancreatic cancer, the varied manifestations lead to treatment-related challenges. Everolimus therapy is generally recommended for patients with advanced pancreatic neuroendocrine tumors; however, its efficacy in a neoadjuvant setting remains unclear. Here we present a case of a giant pancreatic neuroendocrine tumor with a portal tumor thrombus that became resectable after everolimus therapy. Case presentation A 62-year-old woman was admitted to our hospital for surgical resection of a giant pancreatic neuroendocrine tumor in the left upper abdomen. Unfortunately, she was ineligible for surgery because the tumor had extended near the hepatic hilus in the portal vein, and she was administered everolimus (10 mg/day). After 2 years of this therapy, the extent of portal vein involvement had decreased, despite the lack of significant changes in the tumor size, and the hepatic hilus became free of disease. She was subsequently referred to us for resection via distal pancreatectomy with portal vein reconstruction because the tumor had begun to grow slowly. Pathological review identified a grade 2 neuroendocrine tumor with no lymph node metastasis. The patient’s postoperative course was uneventful, and she has remained recurrence-free for 27 months, despite a lack of additional treatment. Conclusions Our experience suggests that everolimus could be useful for neoadjuvant therapy in cases of locally advanced pancreatic neuroendocrine tumor.http://link.springer.com/article/10.1186/s40792-017-0361-8Neuroendocrine tumorEverolimusSunitinib malate68Ga-DOTATOC-PET/CT |
| spellingShingle | Asahi Sato Toshihiko Masui Nao Sankoda Kenzo Nakano Yuichiro Uchida Takayuki Anazawa Kyoichi Takaori Yoshiya Kawaguchi Shinji Uemoto A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor Surgical Case Reports Neuroendocrine tumor Everolimus Sunitinib malate 68Ga-DOTATOC-PET/CT |
| title | A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor |
| title_full | A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor |
| title_fullStr | A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor |
| title_full_unstemmed | A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor |
| title_short | A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor |
| title_sort | case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor |
| topic | Neuroendocrine tumor Everolimus Sunitinib malate 68Ga-DOTATOC-PET/CT |
| url | http://link.springer.com/article/10.1186/s40792-017-0361-8 |
| work_keys_str_mv | AT asahisato acaseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT toshihikomasui acaseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT naosankoda acaseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT kenzonakano acaseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT yuichirouchida acaseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT takayukianazawa acaseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT kyoichitakaori acaseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT yoshiyakawaguchi acaseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT shinjiuemoto acaseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT asahisato caseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT toshihikomasui caseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT naosankoda caseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT kenzonakano caseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT yuichirouchida caseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT takayukianazawa caseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT kyoichitakaori caseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT yoshiyakawaguchi caseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor AT shinjiuemoto caseofsuccessfulconversionfromeverolimustosurgicalresectionofagiantpancreaticneuroendocrinetumor |